Detection and characterization of circulating tumor cells in cancer patients

Detection and characterization of circulating tumor cells in cancer patients - CTC phenotyping

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34754

Enrollment

150

Registered

2010-03-30

Start date

2011-03-17

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer spread Metastasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Minimal age 18 years Diagnosis Stage IV solid carcinoma Minimum of seven days since last therapie (exept daily administration therapies) Signed informed consent form

Exclusion criteria

Exclusion criteria: Under the age of 18 years Early stage disease Patients unwilling/unable to give consent

Design outcomes

Primary

Measure	Time frame
The blood specimens will be used to isolate, enumerate, and characterize the circulating cells. Fluorescently labeled antibodies for tumor specific and/or tissue specific markers among others will be used to identify, count and characterize the circulating cells. The blood samples and isolated cells may also be used for the detection of altered, over-, or under-produced cancer-related molecules, including gene expression studies of genes that may be related to the response of cancer cells to therapeutics. Genetic studies will be done to determine their importance in response to therapies, not to test for genetic sequences for the purpose of identifying inherited genetic disorders. Remaining blood samples and their components may be saved for possible use in future investigations related to cancer research, including detection of altered, over-, or under-produced cancer-related molecules.	—

Measure

Time frame

The blood specimens will be used to isolate, enumerate, and characterize the circulating cells. Fluorescently labeled antibodies for tumor specific and/or tissue specific markers among others will be used to identify, count and characterize the circulating cells. The blood samples and isolated cells may also be used for the detection of altered, over-, or under-produced cancer-related molecules, including gene expression studies of genes that may be related to the response of cancer cells to therapeutics. Genetic studies will be done to determine their importance in response to therapies, not to test for genetic sequences for the purpose of identifying inherited genetic disorders. Remaining blood samples and their components may be saved for possible use in future investigations related to cancer research, including detection of altered, over-, or under-produced cancer-related molecules.

—

Countries

Netherlands

Outcome results